Detecting cervical cancer using optical technology
Cervical Cancer Detection Using Optical Spectroscopy
This study is testing new optical technology to see if it can help doctors better detect cervical cancer in women undergoing colposcopy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Duke University Academic / other |
| Locations | 1 site (Durham, North Carolina) |
| Trial ID | NCT00900575 on ClinicalTrials.gov |
What this trial studies
This study aims to identify the optical signatures associated with cervical dysplasia through the use of advanced optical technologies. Participants undergoing colposcopy for cervical cancer diagnosis or treatment will be evaluated using an optical spectroscopy bench-top system and a portable optical spectrometer. The goal is to enhance the accuracy of cervical cancer detection and improve patient outcomes. The study will involve both diagnostic and follow-up procedures to assess the effectiveness of these optical methods.
Who should consider this trial
Good fit: Ideal candidates are women undergoing colposcopy for cervical cancer diagnosis or treatment.
Not a fit: Patients under 18 years old or those with recent bleeding or preterm labor may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and less invasive methods for detecting cervical cancer.
How similar studies have performed: Other studies using optical technologies for cancer detection have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * undergoing colposcopy for the diagnosis of cervical cancer * LEEP for the treatment of cervical cancer in early stages. * Follow-up Pap smear in surveillance Exclusion Criteria: * Women under the age of 18 (minors) will be excluded from this study. * patients will be excluded if she has had a recent episode of bleeding or preterm labor. * Subjects who are not competent to give consent will excluded
Where this trial is running
Durham, North Carolina
- Duke University Medical Center — Durham, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Nimmi Ramanujam, Ph.D. — Duke University
- Study coordinator: Nimmi Ramanujam, Ph.D.
- Email: nimmi@duke.edu
- Phone: 919-660-5307
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.